Evidence map›Paper›PMID 38002340›Full record

ArticleBiomolecules2023

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.

Vladimir M Pogorelov, Michael L Martini, Jian Jin, William C Wetsel, Marc G Caron

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vladimir M PogorelovDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, 354 Sands Building, 303 Research Drive, Durham, NC 27710, USA.
Michael L MartiniMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-2387-3862
William C WetselDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, 354 Sands Building, 303 Research Drive, Durham, NC 27710, USA.
Marc G CaronDepartment of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA.
Duke University · USIcahn School of Medicine at Mount Sinai · US

Funding

Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's SymptomsR01NS100930 · NINDS · DUKE UNIVERSITY · PI CARON, MARC G. · 2017 to 2021
$3.2M
NINDS NIH HHS R01 NS100930NINDS NIH HHS R01NS100930
6 · The paper itself

Abstract

L-DOPA is the mainstay of treatment for Parkinson's disease (PD). However, over time this drug can produce dyskinesia. A useful acute PD model for screening novel compounds for anti-parkinsonian and L-DOPA-induced dyskinesia (LID) are dopamine-depleted dopamine-transporter KO (DDD) mice. Treatment with α-methyl-

Indexed as

Dyskinesia, Drug-InducedParkinson DiseaseAmantadineAnimalsDopamineDopamine AgonistsDopamine Plasma Membrane Transport ProteinsLevodopaMiceMice, KnockoutAmantadineDopamineDopamine AgonistsDopamine Plasma Membrane Transport ProteinsLevodopadopaminedopamine D1 agonistsdopamine transporter knockout micedyskinesiaL-DOPAParkinson’s disease

Identifiers

PMID38002340
PMCPMC10669682
OpenAlexW4388771223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.